PRME Key Statistics, Chart & Performance
The current stock price of PRME is 3.5 USD. In the past month the price decreased by -5.66%. In the past year, price increased by 20.69%.
PRME Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About PRME
Company Profile
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 214 full-time employees. The company went IPO on 2022-10-20. The company deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. The company is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.
Company Info
PRIME MEDICINE INC
60 First St.
Cambridge MASSACHUSETTS US
Employees: 214
Phone: 16174650013
PRIME MEDICINE INC / PRME FAQ
What does PRIME MEDICINE INC do?
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 214 full-time employees. The company went IPO on 2022-10-20. The company deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. The company is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.
What is the current price of PRME stock?
The current stock price of PRME is 3.5 USD. The price decreased by -1.96% in the last trading session.
Does PRME stock pay dividends?
PRME does not pay a dividend.
What is the ChartMill technical and fundamental rating of PRME stock?
PRME has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for PRME stock?
17 analysts have analysed PRME and the average price target is 6.59 USD. This implies a price increase of 88.39% is expected in the next year compared to the current price of 3.5.
Who owns PRIME MEDICINE INC?
You can find the ownership structure of PRIME MEDICINE INC (PRME) on the Ownership tab.
PRME Technical Analysis
PRME Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRME. No worries on liquidiy or solvency for PRME as it has an excellent financial health rating, but there are worries on the profitability.
PRME Financial Highlights
Over the last trailing twelve months PRME reported a non-GAAP Earnings per Share(EPS) of -1.44. The EPS increased by 30.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.26% | ||
| ROE | -121.95% | ||
| Debt/Equity | 0 |
PRME Forecast & Estimates
17 analysts have analysed PRME and the average price target is 6.59 USD. This implies a price increase of 88.39% is expected in the next year compared to the current price of 3.5.
For the next year, analysts expect an EPS growth of 19.72% and a revenue growth 566.68% for PRME